Brought to you by 
Saegis licenses CNS compound from Lilly
04 Nov 2002
Executive Summary
Saegis Pharmaceuticals (1999 start-up that acquires and clinically develops drugs to protect and enhance mental function; originally named David Pharmaceuticals) has licensed from Eli Lilly a compound that has demonstrated an effect on learning and memory in tests on animals.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Saegis licenses CNS compound from Lilly
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice